Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 29, 2026

ING posts FY2025 net result of €6,327 million, driven by continued growth in customer balances and fee income

View original at finance.yahoo.com
ING posts FY2025 net result of €6,327 million, driven by continued growth in customer balances and fee income ING Group ING posts FY2025 net result of €6,327 million, driven by continued growth in customer balances and fee income Full-year profit before tax of €9,148 million and full-year return on equity of 13.2% • Mo…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Our mobile primary customer base has increased by over one million, fully in line with our target, bringing us to more than 15 million mobile primary customers out of nearly 41 million total customers

    80% confidence
  • We achieved strong volume growth, including €56.9 billion in lending growth, more than double the amount of the previous year

    80% confidence
  • ING's management of ESG material risk is 'Strong' with an ESG risk rating of 18.0 (low risk)

    80% confidence
  • We have delivered strong commercial growth while achieving €23.0 billion in total income

    80% confidence
  • We remain committed to supporting our clients in their sustainability transitions

    80% confidence
  • In 2025, amid ongoing geopolitical uncertainty, we have consistently executed our strategy of accelerating growth, increasing impact and further diversifying our income by doing more business with more customers and clients

    80% confidence
  • We remain confident that our strategy positions us to create value for all our stakeholders by supporting more customers and clients, and by diversifying income streams

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
ING posts FY2025 net result of €6,327 million, driven by continued growth in customer balances and fee income — Source | Via News | Finance Via News